omniture

Global Pharmatech Receives a New Patent

Global Pharmatech, Inc.
2006-11-10 13:44 1829


CHANGCHUN, China, Nov. 10 /Xinhua-PRNewswire/ --Global Pharmatech, Inc.

(OTC Bulletin Board: GBLP) a company that develops, manufactures and markets

proprietary botanical drugs and dietary supplements, today announced that the

State Intellectual Property Office of the P. R. China has recently granted a

new innovation patent to one of its botanical drug candidates, XNYDT

(Xianniuyaoditong) granule (patent number: ZL200310109939.3) to Natural

Pharmatech (Jilin), a wholly owned subsidiary of Global Pharmatech, Inc.

(Logo: http://www.prnasia.com/sa/200611101343.JPG )

The drug was developed according to previous clinical experience of

traditional Chinese medicine. XNYDT granule is potentially indicated for the

treatment of lumbosacral pain. Investigational New Drug (IND) application of

XNYDT was approved by the SFDA, Chinese regulatory authority on June 1, 2005.

Global Pharmatech is ready to start clinical development of this product.

XNYDT is a botanical drug product, which is formulated using modern

pharmaceutical technologies. Estimated cost of producing XNYDT is relatively

lower than other traditional herbal products for the treatment of lumbosacral

pain. Based on the data obtained from preliminary tests and previous clinical

experiences of traditional Chinese medicine, this product is expected to have

reasonable safety profile and to be more efficacies in comparison to other

botanical products for the same indication on Chinese market.

Lumbosacral pain is one of common chronic clinical problems in China. It

could be induced by various causes. Dr. Xiaobo Sun, President and CEO of

Global Pharmatech indicated: “We are very glad to have a new drug candidate

on our pipeline. This product will bring our company into a new therapeutic

area. We believe that we will complete our clinical program of XNYDT for the

SFDA market approval within the next three to four years.”

About Global Pharmatech

Global Pharmatech, through its subsidiaries, develops, manufactures and

markets proprietary drugs that are based on Traditional Chinese Medicine

using modern facilities and advanced R&D technologies. The company offers a

full range of start-to-finish biotech services, from research and testing to

manufacture and sale of liquid and solid dose products. The Company employs

unique proprietary extraction methods and also licenses patents and

technologies for botanical/biological drug products. Global Pharmatech’s

operations are currently based in the People’s Republic of China with sales

distribution centers in China, Malaysia, Singapore and Indonesia. For more

information, please visit Global Pharmatech.com

Safe Harbor Statement under the Private Securities Litigation Reform Act

of 1995

This news release contains forward-looking statements within the meaning

of the “safe harbour” provisions of the Private Securities Litigation

Reform Act of 1995. These statements are based upon our current expectations

and speak only as of the date hereof. Our actual results may differ

materially and adversely from those expressed in any forward-looking

statements as a result of various factors and uncertainties, including our

ability to successfully develop and commercialize products, competitive

products in our key markets, changes in consumer demand for our products,

legislative, regulatory and competitive developments and general economic

conditions. Our SEC filings discuss some of the important risk factors that

may affect our business, results of operations and financial condition. We

undertake no obligation to revise or update publicly any forward-looking

statements for any reason.

Source: Global Pharmatech, Inc.
collection